Akorn Inc. (Nasdaq: AKRX) has acquired rights to three new products for $52.8 million.

Akorn is buying eye drop brands AzaSite, Cosopt and Cosopt PF from pharmaceutical company Merck & Co. Inc. (NYSE: MRK).

The deal should strengthen Akorn’s product portfolio. The company, headquartered in Lake Forest, Ill., develops and sells pharmaceuticals, including eye-care products.

Other recent pharmaceutical deals include Shire plc’s purchase of ViroPharma Inc.for $4.2 billion, and the Paws Pet Co. Inc.’s acquisition of Mesa Pharmacy

 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.